Bioqube Ventures logo

Bioqube Ventures

Europe, Limburg, Belgium, Hasselt

Description

Bioqube Ventures is a specialist life sciences venture capital investor investing in European biotechnology companies

Investor Profile

Bioqube Ventures has made 14 investments, with 5 in the past 12 months and 36% as lead.

Stage Focus

  • Seed (36%)
  • Series A (21%)
  • Series B (21%)
  • Series C (7%)
  • Series D (7%)
  • Series Unknown (7%)

Country Focus

  • United States (21%)
  • France (14%)
  • The Netherlands (14%)
  • United Kingdom (14%)
  • Denmark (14%)
  • Ireland (14%)
  • Germany (7%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Life Science
  • Medical
  • Health Care
  • Oncology
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Bioqube Ventures frequently co-invest with?

Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 3
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 3
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
PH
North America, Minnesota, United States, Minneapolis
Co-Investments: 2
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Acorn Bioventures
North America, New York, United States, New York
Co-Investments: 2
PremjiInvest
Asia, Karnataka, India, Bangalore
Co-Investments: 2
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2
Invus
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by Bioqube Ventures?

Commit Biologics

Aarhus, Midtjylland, Denmark

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.

BiotechnologyLife ScienceMedicalTherapeutics
SeedJan 28, 2025
Amount Raised: $5,737,378
SynOx Therapeutics

Dublin, Dublin, Ireland

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

BiotechnologyMedicalTherapeutics
Series BOct 30, 2024
Amount Raised: $92,000,000
CatalYm

Planegg, Bayern, Germany

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

BiotechnologyHealth CareMedicalTherapeutics
Series DJul 16, 2024
Amount Raised: $150,000,000
Commit Biologics

Aarhus, Midtjylland, Denmark

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.

BiotechnologyLife ScienceMedicalTherapeutics
SeedMay 9, 2024
Amount Raised: $17,250,804
SynOx Therapeutics

Dublin, Dublin, Ireland

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

BiotechnologyMedicalTherapeutics
Series BApr 22, 2024
Amount Raised: $75,000,000
Bicara Therapeutics

Cambridge, Massachusetts, United States

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

BiopharmaBiotechnologyLife ScienceOncologyTherapeutics
Series CDec 12, 2023
Amount Raised: $165,000,000
Anavo Therapeutics

Leiden, Zuid-Holland, The Netherlands

Anavo Therapeutics provides therapeutic potential of human phosphatase biology.

BiotechnologyLife ScienceTherapeutics
SeedMay 2, 2023
Amount Raised: $9,358,986
Bicara Therapeutics

Cambridge, Massachusetts, United States

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

BiopharmaBiotechnologyLife ScienceOncologyTherapeutics
Series BMar 6, 2023
Amount Raised: $108,000,000
Enhanc3D Genomics

Cambridge, Cambridgeshire, United Kingdom

Enhanc3D Genomics is a functional genomics company exploring the 3D organization of DNA in health and disease.

Biotechnology
Series AOct 20, 2022
Amount Raised: $11,221,758
Tridek-One

Évry, Ile-de-France, France

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

BiotechnologyHealth CareLife Science
Series UnknownSep 15, 2022
Amount Raised: $15,979,993